Cyrcadia is a privately traded company, based in Reno, Nevada. Cyrcadia has achieved three patents through Lifeline Biotechnologies (LLBO), which is a publicly traded company that owns approximately 30% of Cyrcadia.

For further information, please contact Jim Holmes at

Our core science and the basis for our three patents is the discovery of the relationship between disruption of the body’s circadian body rhythms and tissue disruption. Prediction of the impact caused by Circadian rhythm disruption is the basis of the Circadian Health clinical trials. No one has developed a technology that competes with this core science. Many have validated our path of validation and discovery.

2018 published study: Evidence for widespread dysregulation of circadian clock progression in human cancer. Abstract: The ubiquitous daily rhythms in mammalian physiology are guided by progression of the circadian clock. In mice, systemic disruption of the clock can promote tumor growth. In vitro, multiple oncogenes can disrupt the clock.

2016 Published Study: Identification of circadian-related gene expression profiles in entrained breast cancer cell lines reaches the same conclusion. It states in part Cancer cells have broken circadian clocks when compared to their normal tissue counterparts. Moreover, it has been shown in breast cancer that disruption of common circadian oscillations is associated with a more negative prognosis… we observed that breast cancer and non-cancerous cultured cells are able to generate specific circadian expression profiles in response to the serum shock. The rhythmic genes, suggested via microarray and measured in each particular subtype, suggest that each breast cancer cell type responds differently to the circadian synchronization. Full article at

2014 Published Study: Loss of circadian clock gene expression is associated with tumor progression in breast cancer.

Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association between circadian clock genes and prognosis in breast cancer has not been systematically studied. Therefore, we examined the expression of 17 clock components in tumors from 766 node-negative breast cancer patients that were untreated in both neoadjuvant and adjuvant settings. In conclusion, loss of clock genes is associated with worse prognosis in breast cancer. Coordinated co-expression of clock genes, indicative of a functional circadian clock, is maintained in ER+, HER2-, low grade and non-metastasizing tumors but is compromised in more aggressive carcinomas.

A 2013 Article: An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors… The data suggest that the circadian regulation is distorted in colonic neoplastic tissue and that the gene-specific disruption may be also observed in the non-neoplastic tissues. These findings reinforce the role of peripheral circadian clockwork disruption for carcinogenesis and tumor progression.


We have a solid basis for our science and its value in reporting on tissue conditions. For additional publications